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Introduction
In the present investigation the Randomized Clinical Trial (RCT) 
is the “gold standard” for evaluating new therapies or strategies in 
medicine [1]. A low quality in RCTs design or publication, it could lead 
to an underestimation of the risk or even false, using treatments that 
may be less or even harmful, and could produce daily clinical practice 
consequences [2]. So a higher quality in published clinical trials to help 
choose the best therapies for patients.
There are different methods of assessing the ethical quality of Clinical 
Trials (CTs) publications, amongst which Dechartres et al. identified 
26 scales or checklists based on CONSORT (Consolidated Standards 
of Reporting Trials) [3]. In this way they obtained increased data on 
methodological issues, but only 29% adequate masked allocation. They 
also found that quality evaluation still presents significant problems 
[4]. Katrak et al. also observed heterogeneity in the use of criteria and 
unclear definition in the scales, which might limit the relevance of the 
results [5].
No studies have been found assessing the methodological and 
ethical quality of the CTs published in Annals of Family Medicine 
journal. 
The aim is to analyze quantitative and qualitative methodological 
and ethical quality of published clinical trials in Annals of Family 
Medicine journal, between 2010-2013. We chose this journal because 
it has the highest impact factor in Family Medicine (4.613), published 
CTs, CONSORT endorsement and has an important general quality. 
We want to know how clinical trials are performing in primary care, as 
this will help to improve the design and publication of these.
Materials and Methods
On March 25, 2014 we use a hand search and subsequent checklist 
to analyze CTs published in Annals of Family Medicine since January 
1, 2010 to December 31, 2013.
It is a print edition with free online access (no “open access”), which 
follows the CONSORT standards [6,7] and the ICMJE (International 
Committee of Medical Journal Editors) recommendations [8].
We follow the CONSORT statement [3] and PRISMA (Preferred 
Reporting Items for Systematic reviews and Meta-Analyses) [9], which 
provide higher quality checklists [8] for CTs publishing [10,11], and 
have been implemented in over 400 journals and editorial groups as 
ICMJE [3]. We will also use the most recent edition of the Declaration 
of Helsinki (2013) [12,13].
Inclusion and exclusion criteria
We obtained published studies from CONSORT [14] to increase 
the quality [15]. We included all CTs carried out in humans. Exclusion 
criteria were: 1) CT assessing diagnostic test or costs; 2) “Letters to 
the editor” type studies and pilot tests; 3) Continuation CT (as full 
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The “choice of subjects” is the next section (4th). The subjects are 
White in 54.3%, 45.7% African Americans, 37.1% Hispanic and in 8 
studies Asian. Race is not indicated in 42.9%, not specified in 13 CTs, 
and in 4, subjects are ethnic minorities such as American Indian and 
Vietnamese. The inclusion of immigrant or low-income groups has 
increased in the last three years: 2011 (1), 2012 and 2013 (3). We have 
not observed the inclusion of “vulnerable” people [24].
In the 5th section the “sample size” is evaluated. Quantitative 
variables are reported in a table (Table 3). The “alpha” error is 74.3%, 
“beta” is 82.9%, the magnitude of the minimum difference to be found 
is 80%, and the “flowchart” is 85.7%.
Regarding the “Description of treatment” (section 6), with an 
effective standard treatment, placebo or non-intervention has not been 
used as a control in 62.9%. A strong and compelling case for the use of 
placebo or non-intervention for methodological reasons was given in 6 
CTs, and the determination of efficacy and safety in two. In 37.1%, there 
were serious adverse events in general (including death), and it was 
unclear in 3 studies. The “intention to treat analysis” was conducted in 
15 CTs, “not indicated” (to be performed but not mentioned) in 3, and 
was “unclear” (to be mentioned but not performed properly) in one. 
According to the Jadad score, 15 studies were of good quality (3), 16 
low-grade (1 or 2) and 4 excellent (5).
The 7th section deals with the “development of the trial and 
assessment the answer”. The “primary outcome variable” or “endpoint” 
is not described in one CT and is “unclear” in 11.4%. “Multivariate 
analysis” is applied in 42.9%. There is a DSMB in 14.3%. Finally, 
CONSORT standards mentioned that it followed in 28.6%.
Assessment of other ethical quality parameters
In the 8th section, the most important variables are represented 
in Table 2. Two CTs included minors as research subjects. Parents or 
representative completed Informed Consent (IC) in one of them and 
the other this completion was “unclear”.
publications or “short reports”) for the study of secondary variables or 
secondary analysis of a previously published CT with the same number 
of subjects.
Checklist to assess the ethical and methodological quality
We reviewed a checklist [16] based on CONSORT [17] that had 
80 items divided into 8 sections. We have updated to a 133-item 
checklist in eleven sections. It was applied to assess their ethical and 
methodological quality. Following the Declaration of Helsinki [18], 
items were modified or created to adapt them to Primary Care (PC) 
with the assistance of the PRECIS (Pragmatic-Explanatory Continuum 
Indicator Summary) tool [19]. More explicit variables were created 
for placebo use. We introduced AHRQ [20] (“Agency for Healthcare 
Research and Quality”) criteria and the Jadad quality scale. We use 
the assessment by a DSMB (Data and Safety Monitoring Board) and 
“stopping rules” (Haybittle-Peto, Pocock, O’Brien-Fleming) [21]. We 
also evaluated sequential trials, optimized evaluated by the CREC 
(Clinical Research Ethics Committee) or futility analysis. We stressed 
race and language, incentives, training in Bioethics, types of conflicts of 
interest and sponsor influence.
Analysis and data extraction
Two tables with frequency and rates for qualitative variables were 
made. We built a table with the mean, median, mode, minimum, 
maximum and statistical percentiles (P25, P50, P75) for quantitative 
variables. Data were calculated using SPSS 20.0.
Comparable variables on the κ, κ means and 95% CI value was 
obtained [22]. 
This article does not contain any studies with human participants 
or animals performed by any of the authors.
Informed consent was no necessary to obtain because no individual 
participants were included in the study.
Results
We found 35 CTs that met the inclusion criteria (Figure 1). Most 
were observational studies. Afterwards we eliminated three of these 
(not meet the inclusion criteria) and final analysis was performed.
Table 1 shows the frequencies and rates for the most representative 
items.
Assessment of methodological quality
In the section on “justification and objectives” of our checklist, 
we observed that the following appear in all: 1) CT in heading or 
subheading, 2) related CTs, 3) systematic review cited and 4) a priori 
hypothesis.
Regarding the “clinical trial type”, 68.6% were performed in > 5 
centers and 14.3% in ≤ 5. In 80% some authors are epidemiologists or 
statisticians.
In the 3rd section, the “clinical trial design” is evaluated. In 80%, 
there were controlled parallel-groups and controlled factorials in 4 CTs. 
There is a tendency to be more pragmatic than explanatory according 
to the criteria of AHRQ.
Baseline comparison was made in a table following CONSORT [14] 
for almost all CTs (34), and “p” in 68.6%. Only the CT by Licciardone 
et al. [23] is sequential; moreover it uses the O’Brien Fleming stopping 
rule. The effectiveness of masking and withdrawals due to adverse 
events were found in only 5 CTs and the latter were uncertain in 6 
studies (Table 2).
189 original articles from total bimonthly publications or AFM supplements from 2010 to 2013 
151 articles with no clinical trials in manual search 
35 CTs met the inclusion criteria and are evaluated 
38 CTs found by manual search described as CT in the heading/subheading, summary or in materials & methods 
3 CTs did not meet the inclusion criteria 
Figure 1: Flow diagram with the choice of studies for analysis according to 
PRISMA [10].
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VARIABLE VALUE FREQ %
Author nationality USA 24 68.6
United Kingdom 1 2.9
Scandinavia 1 2.9
Other European 5 14.3
Other 4 11.4
Country where the study was 




Type of funding Nonprofit: public 24 68.6
Nonprofit: private 14 40.0*
Pharmaceuticals industry 3 8.6*
Not indicated 3 8.6





Was a masked method of 
randomization followed? Yes 24 68.6
No 7 20.0
Unclear 4 11.4
Was the method of masked 
randomization used specified? Decentralized 16 45.7
Opaque envelopes 
opened sequentially 6 17.1*
Other 5 14.3
Not mentioned 5 14.3
No masked 
randomization 7 20.0
Type of control Placebo 4 11.4
Active treatment 25 71.5*
No treatment 7 20.0*
Other 1 2.9
Is the degree of masking 
assessment indicated? Open or Not blind 16 45.7
Single blind 5 14.3
Double-blind 2 5.7
Blind assessment by 
others 8 22.9
Triple-blind 4 11.4
Does it explain why the trial is 
not blind? Yes 1 2.9
No 13 37.1
Unclear 2 7.7
Blind CT 19 54.3
Is masking method indicated? Yes 12 34.3
No 5 14.3
Unclear 2 5.7
Open CT 16 45.7
Treatment Type Drug already marketed 3 8.6
Medical device 4 11.4
Medical procedure 
method 26 74.3*
Other a 8 22.9*
Trial outcome Therapy significantly improved 16 45.7
No difference 12 34.3
Difference according to 
author but not significant 3 8.6
Other b 1 2.9
Trend toward treatment 3 8.6
Assessment of outcome 
("endpoint") Death 1 2.9
Laboratory diagnosis 9 25.7




Measuring range 5 14.3*
* Sum of several similar variables.  Proportions add up to more than 100% because 
of multiresponse
a Aquaerobic, Yoga… b Significant improvement in primary endpoint but not 
remainder
Table 1: Methodological variables: frequencies and rates.
VARIABLE VALUE FREQ %
Does it mention whether 
informed consent was obtained? Yes 23 65.7
No 12 34.3
Was the informed consent 
obtained voluntarily? Yes 6 17.1
Unclear 18 51.4
No informed consent 11 31.4
Is the type of consent is 
specific, and is it witnessed and 
documented?
Oral (no mention of witness) 1 2.9
Written 11 31.4
Not mentioned (whether 
written/oral) 11 31.4
No informed consent 12 34.3
Does patient receive information 
to obtain informed consent? Yes 5 14.3
No 19 54.3
No informed consent 11 31.4
Is informed consent dependent 
or under pressure? Dependence relationship 10 28.6
No 2 5.7
Unclear 11 31.4
No informed consent 12 34.3
Is a qualified unrelated person 
designated to obtain the IC? Yes 1 2.9
No 6 17.1
Unclear 14 40.0
No informed consent 14 40.0
Is the IC of the subject 





No informed consent 11 31.4
Are researchers, participating 
institutions and/or subjects 
incentivized?
No 16 45.7
To researchers 15 42.9
To participating institutions 3 8.6
To subject involved 3 8.6*
To research assistants 2 5.7
To physician cluster 
involved 3 8.6*
If so, specify the type and 
amount Bonus to researchers 7 20.0
Grant or fellowship for 
researchers 12 34.3*
Bonus to participating 
centers 3 8.6
Bonus to subject involved 3 8.6*
No incentives given 16 45.7
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The confidentiality of the participants’ personal information was 
found in only 17.1%. In 8.6% of the CTs, people were injured by their 
participation, but none were compensated. In 22.9% a study protocol 
is not stated.
In all CTs possible conflicts of interest were stated. The influence 
by the sponsor was not described in 48.6%. The studies reviewed are 
registered in 57.1% of the cases.
Calculation of Kappa index
The authors (FGG and ACG) independently reviewed the 35 
articles chosen following the checklist. For the completion of the 
variables they followed detailed instructions and discrepancies were 
resolved by consensus. In 82 variables we found a κ average of 0.93 
(95% CI, 0.90-0.96), optimal) [25]. In Table 4 the variables assessed by 
κ appear.
Discussion
In current Family Medicine RCT is one of the main tools to 
compare a new treatment with other standard or a placebo. Therefore 
the quality of the publication of new RCTs, is crucial for a reliable 
picture of the results they can obtain in order to implement them safely 
on clinical practice.
Clinical trials published in “Annals of Family Medicine” journal 
are most frequently named in Family Medicine. Therefore, our study 
evaluates the quality of these, for a fairly good idea of how they are 
developing RCTs in Family Medicine. We assess one journal only to 
have a minimal publication bias. 
We observed a higher general quality if we compare our study with 
similar. In a related study [16] there is a progressive increase in masked 
randomization: 33.1% (1993-95), 56.7% (2004) and 68.6% in 2010-13. 
It could be explained because after CONSORT, it was stressed that it 
was essential to reduce selection bias. In contrast, double blind trial is 
less frequent (5.7%) versus earlier revisions (43.9% (1993-1995) and 
43.3% (2004) and placebo use as a control element has also decreased: 
37.0% (93-95), 16.7% (2004) and 11.4% (2010-13). Probably due to the 
treatments used less frequent damaging. The figures for “intention-
to-treat” and “multivariate” analysis remain stable (47.7% and 44.2%, 
42.9% (both), although both were higher in 2004 (70% each). This may 
be due to the increased statistical power searched in recent years. 
Regarding the indicators of ethical quality [16], the number of CTs 
without a reference to CREC has dropped, particularly in the latest 
period (25.5% (93-95), 20% (2004) and 5.7% (2010-13). This is perhaps 
attributable to CONSORT standards. Coinciding with Ndebele et al. 
[12], CTs on children or disabled persons have been very infrequent 
in the three studies. A possible explanation could be that in Family 
Medicine children as research subjects are uncommon.
In Sinha et al. [26], a Jadad score ≥3 was found in 40%, which is 
slightly higher than the rate found in our study (54.3%). This is perhaps 
because there are less RCT.
We agree with Agha et al. [27] that the country where most CTs 
were carried out was the US (15). Possibly because it is the country 
where more research is conducted.
In contrast with our results, O’Meara et al. [28], in their review 
observed very limited information on the sample size and masking. We 
think it could be because most studies reviewed are low quality.
We agree with Laframboise et al. [29] when they describe all the 
justification and objectives. This description is possibly necessary to 
assess the CTs results.
Panic et al. [30] grant and sponsors were described in 70%, which 
is more frequent than in our findings. This could be because “Annals 
Bonus to research assistant 3 8.6
Bonus to physician cluster 
involved 2 5.7
Has the incentive offered been 
provided? Yes 17 48.6
No 2 5.7
No incentives given 16 45.7
Information provided in relation 
to conflict of interest No conflict of interest 28 80.0
Payment or company grant 6 17.1
An author works for 
company 3 8.6*
An author has shares in the 
company 1 2.9
Other a 1 2.9
* Sum of several similar variables. Proportions add up to more than 100% because 
of multiresponse  
a An author had worked as consultant for the company provided an electronic tool 
to help make medical decisions.
Table 2: Ethical variables: frequencies and rates.
VARIABLE MEAN MEDIAN MODE MINIMUM MAXIMUM P25 P50 P75
Subjects evaluated 6403 1102 88 (several) 88 77000 372 1102 3930
Subjects evaluated (cluster) 78 48 40 25 373 38 48 77
Subjects refuse to participate 1080 49 0 0 18882 0 49 245
Subjects refuse to participate (cluster) 3 0 0 0 15 0 0 8
Subjects randomized 1744 417 237 84 21762 231 417 1826
Subjects randomized (cluster) 66 40 27 (several) 19 373 27 40 56
Subjects were assigned treatment 1709 388 237 84 21762 231 388 1771
Subjects were assigned treatment (cluster) 64 40 41 19 373 27 40 54
Subjects withdrew their consent 3 0 0 0 31 0 0 0
Subjects withdrew their consent (cluster) 0 0 0 0 0 0 0 0
"Lost to follow-up" 124 9 0 0 1533 0 9 52
"Lost to follow-up" (cluster) 2 0 0 0 15 0 0 2
Main analysis of a total 1578 378 181 36 21079 181 378 1180
Main analysis of a total (cluster) 64 40 40 (several) 18 372 24 40 54
Case "end point" wished to avoid 326 135 8 (several) 8 1912 44 135 250
Case "end point" wished to avoid (cluster) 3 0 0 0 16 0 0 8
Table 3: Most representative statistic for numeric variables.
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of Family Medicine” RCTs does explain those data less than conflict of 
interest.
Similar to our study, the most common source of funding in Lai et 
al. [31] was public (58.1%), probably because CTs are very expensive. 
In this study, the significant adverse events were common (64.9%), 
possibly by not studying safe medical interventions. Moreover the 
methodological quality is higher in our study, only appear in this review 
in 45.9% the primary endpoint, and sample size calculation in 39.2%, 
masked randomization in 29.7%, blind in 12.2%, and “intention-
to-treat” in 27%. Ifeacho et al. [32] observed lower rates than ours 
in relation to the appearance of CT in the title (40%), description of 
the design (12%), sample size (20%) and random assignment (32%). 
Moreover their study obtained less frequent results regarding the type 
of masking (24%), funding-sponsors (28%) and statistical methods 
(22%). Poolman et al. [33] found fewer cases of an epidemiologist as 
VARIABLE NAME κ
Was the study identified as a clinical trial in the title or subtitle? 1.00
Author nationality 1.00
Country where the study was performed 1.00
Is any earlier related systematic review quoted? 1.00
Is the "a priori" hypothesis explicitly detailed? 1.00
Are there references to an earlier publication of the same clinical trial? 1.00
Clinical trial type with reference to the number of participating centers 0.94
Are an epidemiologist and/or statistician involved as an author? 0.84
Is the collaboration of an epidemiologist and/or statistician indicated? 0.78
Type of funding 0.83
Random allocation system 0.78
Was a method of masked randomization followed? 0.46
Was the method of masked randomization used specified? 0.77
Does it mention if a hypothesis test ("p") was used in the baseline 
comparison of groups? 0.78
Type of control 0.87
Type of clinical trial 0.82
If sequential, are the stopping rules written and what are they? 1.00
Is the clinical trial described as pragmatic? 1.00
Is the degree of masking assessment indicated? 0.79
Does it explain why the test is not blind? 0.90
Is the masking method indicated? 0.82
Does it indicate that the effectiveness of blinding was assessed? 0.95
Population type by age 1.00
Race of participant subjects indicated (cluster: also physicians) in the 
trial 0.95
Language of participant subjects indicated (cluster: also physicians) 1.00
Subject type 1.00
Does it mention whether the "alpha" error was taken into account in 
obtaining the sample size? 0.80
Does it mention whether the "beta" error was taken into account in 
obtaining the sample size? 0.83
Was the magnitude of minimum difference taken into account in 
calculating the sample size? 0.85
Is a flowchart of patients shown? 1.00
Are there withdrawals due to side effects (in the flowchart or text)? 0.91
Treatment Type 0.95
Placebo used or no intervention, if standard treatment is effective? 0.74
If the answer is "1. Yes", why? 0.77
Has the use of placebo or no intervention made patients run additional 
risk of serious or irreversible damage? 0.77
Is the presence of permitted and/or prohibited concomitant therapies 
indicated? 0.71
Trial outcome 0.71
Were negative or inconclusive clinical trial results published? 1.00
Is the primary response variable explicitly indicated? 1.00
Assessment of outcome ("endpoint") 1.00
Was the clinical trial finalized sooner than scheduled? 1.00
Why the trial was stopped earlier than scheduled specified 1.00
Is "intention to treat analysis" carried out? 1.00
Are the values  of "p" or "confidence intervals" (CI) indicated? 0.82
Does it indicate whether a multivariate analysis was performed? 0.83
Is there an agency for data monitoring and safety such as the DSMB? 0.80
Are there serious adverse events in general? 0.88
Were there any amendments to the protocol during the course of the 
trial? 1.00
If so, has the ethics committee been informed? 1.00
Is it specified whether the trial follows the CONSORT standards? 1.00
Is it mentioned whether an ethics committee has approved the clinical 
trial? 1.00
If so, is the appropriate ethics committee mentioned? 1.00
Have the potential subjects included in the study been informed of 
different aspects of the clinical trial? 1.00
If the answer is yes, have they understood this information and has this 
been confirmed? 1.00
Does it mention if informed consent was obtained? 1.00
Was the informed consent obtained voluntary? 1.00
If "Yes" to question 95, is the type of consent specified, and is it 
witnessed and documented? 0.96
Does it indicate whether a parent/legal guardian in the case of minors or 
incompetent adults gave it? 1.00
If the IC was not obtained from legal representatives (not available), and 
the CT could not be delayed, was it obtained as soon as possible? 1.00
Has the disagreement of the potential subject, either a minor or 
incompetent, been respected, and IC conformity been given by his/her 
legal representative?
1.00
Do incompetent or minor subjects, who cannot give IC, participate as a 
necessary characteristic of the researched group? 1.00
Does it specify any information received by the patient at the time of 
obtaining informed consent? 0.95
Has the IC request been made under pressure or dependence?  1.00
Following the previous answer, was a properly qualified unrelated 
person designated in order to obtain consent? 1.00
Did any individual participant withdraw consent at any time during the 
investigation? 1.00
Were precautions taken on the confidentiality of personal information of 
subjects participating in the clinical trial? 1.00
Was informed consent to save and use the data obtained in the future 
given by subjects participating in clinical trials? 1.00
If the answer was "2. No," did a research ethics committee carry out the 
clinical trial after approval? 1.00
Are people injured by their participation in the study shown? 1.00
If they have been injured, have they been compensated for the harm 
they suffered? 1.00
If injury is caused to subjects participating, does the protocol cover the 
repair of such injury, so there are no side effects for any subject? 1.00
In the protocol, are arrangements outlined for the less beneficial 
interventions after finishing in order to equate all participants? 1.00
At the end, was the intervention identified as most beneficial provided for 
other participants who had not received it? 1.00
In accordance with the above answer, they were informed of this fact in 
the informed consent? 1.00
Have you informed all participating subjects of the overall results of the 
study? 1.00
Was any incentive offered to researchers, participating centers and/or 
subjects? 1.00
If so, specify the type and amount 1.00
If an incentive was offered, has it been provided and why so or not? 1.00
Is information given on whether there is a conflict of interest? 1.00
Type of information provided in relation to conflict of interest 1.00
Influence of the sponsor in writing, reviewing and/or publication of results 1.00
Is the clinical trial been registered? 1.00
Table 4: Variables with corresponding κ value.
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author (9%), multicenter types and following of CONSORT (13%) 
standards than in our study. We believe it might be because the 
journals assessed in these studies did not follow CONSORT standards 
completely.
Anttila et al. [34] performed after CONSORT, obtained similar 
results to ours on justification, objectives and design.
In 2011 Kiehna et al. [35] found data with rates lower than our 
study in the justification and design, in contrast with the description 
of significant adverse events. The sequence of randomization (41%), 
the analyses of “intention-to-treat” (33%) and masking (19%) were 
also significantly lower than those included in our review. Augestad 
et al. [36] observed less frequency of CT registration (25%), funding 
(95%), performing in PC (70%) and masking type (15.6%). The mean 
Jadad score was 2, also below our findings. This is perhaps because they 
assessed more pharmacological studies with questionable quality.
Coinciding with Baskerville et al. [11] we only have access to 
the published CT and not the original data (that may differ). There 
is variability between the studies regarding the measurement of the 
“endpoints”, due to the many types of variables found by the study 
treatment.
Would be desirable a study based on an analysis of disciplines, 
specialties or a particular subject in the future.
The authors recommend that a greater emphasis on proper 
implementation of the CONSORT standards, could take an 
improvement in quality of Family Medicine clinical trials published.
Therefore, a deeper insight into obtain a better methodological and 
ethical quality, it will lead us to further analysis in the evaluation of a 
new medical treatment before use with patients. In this way, it could 
avoid many of the side effects or ineffectiveness of new therapies, so 
that when they were cast safe and effective into the public. This also 
would be a great saving for the health system costs and potential 
demands of patients in the future.
Conclusions
We observe that the most frequent CT published in Annals of Family 
Medicine (2010-2013) are: multicenter >5, with public funding, cluster 
controlled open parallel, with decentralized masked randomization 
using an active treatment as a control, in a 6-12 months period; made 
up of in a biracial patient group and applying a method of medical 
intervention with positive results in 50% (measured by questionnaire). 
In 50% the intention-to-treat analyses are performed, and they show 
serious adverse events and good quality (Jadad 3). Furthermore, IC 
(verbal or not mentioned), no incentive and no conflicts of interest 
occur more frequently than in other publications cited. Lastly, we find 
optimal κ.
Following the CONSORT standards publication, it has increased 
the overall quality of the CTs published. But there are some areas for 
improvement in the methodological and ethical quality of the CTs 
published from 2010 to 2013 in Annals of Family Medicine.
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